NcXHF

DECISION MAKING IN THE CONTEXT OF BREAST CANCER CHEMOPREVENTION
References
1. WHO. Breast cancer: prevention and control. http://www.who.int/cancer/detection/breastcancer/en.
Accessed July 25, 2014.
2. National Cancer Institute. SEER stat fact sheets: breast cancer. http://
seer.cancer.gov/statfacts/html/breast.html. Accessed July 25, 2014.
3. Kruk J. Association between vegetable, fruit and carbohydrate intake
and breast cancer risk in relation to physical activity. Asian Pac J Cancer
Prev. 2014;15:4429-4436.
4. Gaudet MM, Britton JA, Kabat GC, et al. Fruits, vegetables, and micronutrients
in relation to breast cancer modifıed by menopause and hormone
receptor status. Cancer Epidemiol Biomarkers Prev. 2004;13:1485-
1494.
5. Jung S, Spiegelman D, Baglietto L, et al. Fruit and vegetable intake and
risk of breast cancer by hormone receptor status. J Natl Cancer Inst.
2013;105:219-236.
6. Aune D, Chan DS, Vieira AR, et al. Fruits, vegetables and breast cancer
risk: a systematic review and meta-analysis of prospective studies. Breast
Cancer Res Treat. 2012;134:479-493.
7. Rockhill B, Kawachi I, Colditz GA. Individual risk prediction and
population-wide disease prevention. Epidemiol Rev. 2000;22:176-180.
8. Cuzick J, DeCensi A, Arun B, et al. Preventive therapy for breast cancer:
a consensus statement. Lancet Oncol. 2011;12:496-503.
9. Brewster AM, Davidson NE, McCaskill-Stevens W. Chemoprevention
for breast cancer: overcoming barriers to treatment. Am Soc Clin Oncol
Educ Book. 2012;85-90.
10. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention
of breast cancer: current status of the National Surgical Adjuvant
Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:
1652-1662.
11. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs
raloxifene on the risk of developing invasive breast cancer and other
disease outcomes: the NSABP Study of Tamoxifen and Raloxifene
(STAR) P-2 trial. JAMA. 2006;295:2727-2741.
12. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National
Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and
Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res
(Phila). 2010;3:696-706.
13. Waters EA, Cronin KA, Graubard BI, et al. Prevalence of tamoxifen use
for breast cancer chemoprevention among U.S. women. Cancer Epidemiol
Biomarkers Prev. 2010;19:443-446.
14. Waters EA, McNeel TS, Stevens WM, et al. Use of tamoxifen and raloxifene
for breast cancer chemoprevention in 2010. Breast Cancer Res
Treat. 2012;134:875-880.
15. Freedman AN, Graubard BI, Rao SR, et al. Estimates of the number of
US women who could benefıt from tamoxifen for breast cancer chemoprevention.
J Natl Cancer Inst. 2003;95:526-532.
16. Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer
chemoprevention: a systematic review and meta-analysis. J Clin Oncol.
2010;28:3090-3095.
17. Tchou J, Hou N, Rademaker A, et al. Acceptance of tamoxifen chemoprevention
by physicians and women at risk. Cancer. 2004;100:1800-
1806.
18. McKay A, Martin W, Latosinsky S. How should we inform women at
higher risk of breast cancer about tamoxifen? An approach with a decision
guide. Breast Cancer Res Treat. 2005;94:153-159.
19. McKay A, Latosinsky S, Martin W. Acceptance of tamoxifen chemoprevention
by physicians and women at risk. Cancer. 2005;103:209-
210.
20. Donnelly LS, Evans DG, Wiseman J, et al. Uptake of tamoxifen in consecutive
premenopausal women under surveillance in a high-risk breast
cancer clinic. Br J Cancer. 2014;110:1681-1687.
21. Gorin SS, Wang C, Raich P, et al. Decision making in cancer primary
prevention and chemoprevention. Ann Behav Med. 2006;32:179-
187.
22. Juraskova I, Bonner C. Decision aids for breast cancer chemoprevention.
Breast Cancer Res. 2013;15:106.
23. Fagerlin A, Dillard AJ, Smith DM, et al. Women’s interest in taking tamoxifen
and raloxifene for breast cancer prevention: response to a tailored
decision aid. Breast Cancer Res Treat. 2011;127:681-688.
24. Fagerlin A, Zikmund-Fisher BJ, Nair V, et al. Women’s decisions regarding
tamoxifen for breast cancer prevention: responses to a tailored
decision aid. Breast Cancer Res Treat. 2010;119:613-620.
25. Ozanne EM, Howe R, Omer Z, et al. Development of a personalized
decision aid for breast cancer risk reduction and management. BMC
Med Inform Decis Mak. 2014;14:4.
26. Ozanne EM, Annis C, Adduci K, et al. Pilot trial of a computerized decision
aid for breast cancer prevention. Breast J. 2007;13:147-154.
27. Ozanne EM, Wittenberg E, Garber JE, et al. Breast cancer prevention:
patient decision making and risk communication in the high risk setting.
Breast J. 2010;16:38-47.
28. Heisey R, Pimlott N, Clemons M, et al. Women’s views on chemoprevention
of breast cancer: qualitative study. Can Fam Physician. 2006;52:
624-625.
29. Paterniti DA, Melnikow J, Nuovo J, et al. “I’m going to die of something
anyway”: women’s perceptions of tamoxifen for breast cancer risk reduction.
Ethn Dis. 2005;15:365-372.
30. Fehniger J, Livaudais-Toman J, Karliner L, et al. Perceived versus objective
breast cancer risk in diverse women. J Womens Health (Larchmt).
2014;23:420-427.
31. Taylor R, Taguchi K. Tamoxifen for breast cancer chemoprevention:
low uptake by high-risk women after evaluation of a breast lump. Ann
Fam Med. 2005;3:242-247.
32. Waters EA, Weinstein ND, Colditz GA, et al. Aversion to side effects in
preventive medical treatment decisions. Br J Health Psychol. 2007;12:
383-401.
33. Waters EA, Weinstein ND, Colditz GA, et al. Explanations for side effect
aversion in preventive medical treatment decisions. Health Psychol.
2009;28:201-209.
34. Scherer LD, Ubel PA, McClure J, et al. Belief in numbers: when and why
women disbelieve tailored breast cancer risk statistics. Patient Educ
Couns. 2013;92:253-259.
35. Kaplan CP, Kim SE, Wong ST, et al. Willingness to use tamoxifen to
prevent breast cancer among diverse women. Breast Cancer Res Treat.
2012;133:357-366.
36. Ralph AF, Ager B, Bell ML, et al. Women’s preferences for selective estrogen
reuptake modulators: an investigation using protection motivation
theory. Patient Educ Couns. 2014;96:106-112.
37. Salant T, Ganschow PS, Olopade OI, et al. “Why take it if you don’t have
anything?” breast cancer risk perceptions and prevention choices at a
public hospital. J Gen Intern Med. 2006;21:779-785.
38. Altschuler A, Somkin CP. Women’s decision making about whether
or not to use breast cancer chemoprevention. Women Health. 2005;
41:81-95.
39. Samerski S. Die verrechnete Hoffnung. Von der selbstbestimmten Entscheidung
durch genetische Beratung. Münster. Westfälisches Dampfboot.
2002.
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK
e63